MILAAN – (BUSINESS WIRE) – Deenova meldde vandaag dat haar ongeëvenaarde marktimpuls in 2020 onophoudelijk uitbreidt naar Spanje, met de eerste openbare aanbesteding gewonnen door Deenova van het Bellvitge University Hospital en het Catalan Institute of Health, en afzonderlijk het bedrijf Algalasa voor privéziekenhuizen overal Spanje.

Jose Luis Temes, MD, president van Algalasa en voormalig gezondheidssecretaris bij het Spaanse ministerie van Volksgezondheid, directeur van de nationale gezondheidsdienst in Spanje en directeur van meerdere Spaanse ziekenhuizen, waaronder Stichting Jimenez Diaz, Hospital La Paz en Hospital Queen Sofia, voegde toe : “We zijn erg blij en trots om Deenova-oplossingen te gebruiken om ons portfolio compleet te maken. In Algalasa staan ​​we bekend als experts in het leveren van eersteklas oplossingen voor de automatisering van medicatieworkflow en medische apparatuur in ziekenhuizen en apotheken. Deenova-producten hebben een unieke technologie en business benadering van ROI in de gezondheidszorg die tegelijkertijd de veiligheid van de patiënt, de tevredenheid van het personeel, de kwaliteit en de efficiëntie van de apotheekprocessen verbetert, met gebruikmaking van een opmerkelijk gesloten kringloopsysteem, van het voorschrijven tot aan de toediening aan het bed. ”

Despite COVID-19, Deenova Wins First Pharmacy Automation Contracts in Spain

MILAN–(BUSINESS WIRE)– Deenova reported today that its unrivalled market impulse in 2020 unceasingly expands to Spain, with its first public tender won by Deenova from Bellvitge University Hospital and the Catalan Institute of Health, and separately the company Algalasa for private hospitals throughout Spain.

Jose Luis Temes, M.D., Algalasa’s President and former Subsecretary of Health at Spain Ministry of Health, Director of National Health Service in Spain, and Managing Director of multiple Spanish hospitals, including Foundation Jimenez Diaz, Hospital La Paz, and Hospital Queen Sofia, added: “We are very happy and proud to incorporate Deenova solutions to complete our portfolio. In Algalasa we are known experts in providing first class solutions for the automation of medication workflow and medical devices at hospitals and pharmacies. Deenova products have a unique technology and business approach to R.O.I. in the health care market that simultaneously improves patient safety, staff satisfaction, quality and efficiency of the pharmacy processes, utilising a remarkable closed-loop-system process from prescription all the way to bedside administration.”

Fulvio Rudello, Deenova Chief Operating Officer, added: “As Deenova’s team leader in the design of our next generation mechatronics pharmacy robot, it was crucial to set a very high bar for the industry. Our idea and ambition was to deliver a world-class solution not only for oral solid medications, but to fully automatically handle all the packaging pharmaceutical formats of liquid medications, such as vials, syringes, ampoules, and all other formats of patches sachet, and suppositories. Everyone at Deenova is very proud of leap-frogging other automation and robotic products in the industry”.

Bellvitge University Hospital is located in Hospitalet de Llobregat, Barcelona. With its 900+ beds, it is a public tertiary reference center for a community of more than 200.000 inhabitants at the entire southern axis of Catalonia up to the Ebro river, and part of the Catalan Institute of Health. The Bellvitge University Hospital Campus also houses the University of Barcelona, the Catalan Institute of Oncology, and the IDEBELL Research Institute, for more information, refer to https://bellvitgehospital.cat

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005518/en/

Contacts

Contacts at Deenova:

Christophe Jaffuel, Carlos Duran Ortega, Elisa Mariotti
e.mariotti@deenova.com, +39 0523 785311